Literature DB >> 27149091

Associations between HIV-RNA-based indicators and virological and clinical outcomes.

Kamilla G Laut1, Leah C Shepherd, Court Pedersen, Jürgen K Rockstroh, Helen Sambatakou, Dimitry Paduta, Raimonda Matulionyte, Tomasz Smiatacz, Fiona Mulcahy, Jens D Lundgren, Amanda Mocroft, Ole Kirk.   

Abstract

OBJECTIVES: To evaluate and compare the performance of six HIV-RNA-based quality of care indicators for predicting short-term and long-term outcomes.
DESIGN: Multinational cohort study.
METHODS: We included EuroSIDA patients on antiretroviral therapy (ART) with at least three viral load measurements after baseline (the latest of 01/01/2001 or entry into EuroSIDA). Using multivariate Poisson regression, we modelled the association between short-term (resistance, triple-class failure) and long-term (all-cause mortality, any AIDS/non-AIDS clinical event) outcomes and the indicators: viraemia copy years; consecutive months with viral load ≥ 50 copies/ml; percentage of time on ART spent fully suppressed (%FS); stable on ART; 48 weeks snapshot; and current viral load. Indicators were compared using area under the ROC curve (AUC) and different measures of model fit.
RESULTS: Adjusted incidence rate ratios for all outcomes tended to increase with increasing viraemia copy years, number of consecutive months with viral load ≥ 50 copies/ml, current viral load and with lower %FS, but the gradient of increased risk was weak across strata. None of the indicators reliably identified those at risk of long-term outcomes (AUC 0.54-0.58), but performed consistently better with short-term outcomes [triple class failure (AUC 0.67-0.76) and resistance (AUC 0.64-0.79)]. Goodness of fit varied with the outcome evaluated, but differences between indicators were small.
CONCLUSION: Differences between quality of care indicators were small and no indicator performed consistently better than current viral load. Given the simplicity in assessing and interpreting this indicator, we propose to use current viral load when HIV-RNA-based indicators are used to evaluate the efficacy of ART programs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27149091     DOI: 10.1097/QAD.0000000000001144

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  5 in total

1.  Bias in the estimation of cumulative viremia in cohort studies of HIV-infected individuals.

Authors:  Maia Lesosky; Tracy Glass; Brian Rambau; Nei-Yuan Hsiao; Elaine J Abrams; Landon Myer
Journal:  Ann Epidemiol       Date:  2019-08-23       Impact factor: 3.797

2.  Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015.

Authors:  Kamilla Laut; Leah Shepherd; Roxana Radoi; Igor Karpov; Milosz Parczewski; Cristina Mussini; Fernando Maltez; Marcelo Losso; Nikoloz Chkhartishvili; Hila Elinav; Helen Kovari; Anders Blaxhult; Robert Zangerle; Tatiana Trofimova; Malgorzata Inglot; Kai Zilmer; Elena Kuzovatova; Thérèse Staub; Dorthe Raben; Jens Lundgren; Amanda Mocroft; Ole Kirk
Journal:  Euro Surveill       Date:  2018-05

3.  Non-AIDS Mortality Is Higher Among Successfully Treated People Living with HIV Compared with Matched HIV-Negative Control Persons: A 15-Year Follow-Up Cohort Study in Sweden.

Authors:  Zaake de Coninck; Laith Hussain-Alkhateeb; Göran Bratt; Anna Mia Ekström; Magnus Gisslén; Max Petzold; Veronica Svedhem
Journal:  AIDS Patient Care STDS       Date:  2018-08       Impact factor: 5.078

4.  HIV viraemia during pregnancy in women receiving preconception antiretroviral therapy in KwaDukuza, KwaZulu-Natal.

Authors:  Vuyokazi Ntlantsana; Richard J Hift; Wendy P Mphatswe
Journal:  South Afr J HIV Med       Date:  2019-04-10       Impact factor: 2.744

5.  Factors Associated With Early Virological Response in HIV-Infected Individuals Starting Antiretroviral Therapy in Brazil (2014-2015): Results From a Large HIV Surveillance Cohort.

Authors:  Mariana V Meireles; Ana Roberta P Pascom; Elisabeth C Duarte
Journal:  J Acquir Immune Defic Syndr       Date:  2018-08-01       Impact factor: 3.731

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.